Sean Gaine Selected Research

Epoprostenol Receptors

1/2022	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
1/2021	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
1/2021	Real-world experience of selexipag titration in pulmonary arterial hypertension.
1/2019	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
1/2018	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.
12/2015	Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sean Gaine Research Topics

Disease

21	Pulmonary Arterial Hypertension 01/2022 - 11/2011
8	Pulmonary Hypertension 10/2021 - 09/2006
4	Disease Progression 01/2022 - 01/2019
4	Venous Thromboembolism 12/2020 - 11/2011
3	COVID-19 01/2022 - 01/2021
2	Congenital Heart Defects (Congenital Heart Defect) 01/2020 - 01/2019
2	Lung Diseases (Lung Disease) 01/2020 - 06/2012
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2020 - 01/2017
1	Thrombophilia 01/2022
1	Fatigue 10/2021
1	Pulmonary Embolism 12/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 12/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018
1	Mixed Connective Tissue Disease (MCTD) 01/2018
1	Castleman Disease (Castleman's Disease) 01/2018
1	Rheumatoid Arthritis 01/2018
1	Hypertension (High Blood Pressure) 07/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 03/2016
1	Coronary Disease (Coronary Heart Disease) 03/2016
1	Heart Failure 03/2016
1	Pain (Aches) 12/2015
1	Nausea 12/2015
1	Headache (Headaches) 12/2015
1	Diarrhea 12/2015
1	Hypoxia (Hypoxemia) 08/2008
1	Familial Primary Pulmonary Hypertension 09/2006

Drug/Important Bio-Agent (IBA)

12	selexipagIBA 01/2022 - 12/2015
7	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021 - 12/2015
6	Epoprostenol ReceptorsIBA 01/2022 - 12/2015
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2006
3	edoxabanIBA 12/2020 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2018
2	Endothelin Receptor AntagonistsIBA 01/2020 - 12/2015
2	Phosphodiesterase 5 InhibitorsIBA 01/2020 - 12/2015
1	Heparin (Liquaemin)FDA LinkGeneric 01/2022
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022
1	Thrombin FDA Link 01/2022
1	Platelet Factor 4IBA 01/2021
1	P-SelectinIBA 01/2021
1	Adenosine Diphosphate (ADP)IBA 01/2021
1	SelectinsIBA 01/2021
1	Thrombopoietin (c-mpl Ligand)IBA 01/2021
1	Warfarin (Coumadin)FDA LinkGeneric 12/2020
1	treprostinil FDA Link 01/2020
1	Carbon MonoxideIBA 01/2020
1	pro-brain natriuretic peptide (1-76)IBA 01/2019
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2019
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2018
1	macitentanIBA 01/2018
1	tocilizumab (atlizumab)FDA Link 01/2018
1	Interferon-betaIBA 05/2015
1	CytokinesIBA 01/2015
1	LigandsIBA 06/2012
1	Proteins (Proteins, Gene)FDA Link 08/2008
1	Chemokine CXCL12IBA 08/2008
1	FenfluramineIBA 09/2006
1	Dexfenfluramine (Redux)IBA 09/2006

Therapy/Procedure

11	Therapeutics 01/2022 - 11/2011
2	Critical Care (Surgical Intensive Care) 01/2021 - 01/2021
2	Endarterectomy (Thromboendarterectomy) 05/2016 - 11/2011
1	Activities of Daily Living (ADL) 10/2021
1	Operative Surgical Procedures 01/2021
1	Obstetric Surgical Procedures 01/2021
1	Immunomodulation 01/2018
1	Perioperative Period 05/2016
1	Lung Transplantation 10/2009